Redwood City, Calif.-based iSchemaView has received FDA clearance for RAPID CTA, the company’s 3D imaging solution for computed tomography angiography. RAPID CTA is the newest addition to iSchemaView’s neuroimaging platform—including RAPID CTP and RAPID MRI—which is designed to provide physicians with fast, fully automated imaging that facilitates clinical decision-making around cerebrovascular disease, such as stroke.
In simplest terms, CTA provides visualization of blood vessels in the brain. Using an injectable contrast agent, high-tech x-ray imaging and sophisticated computer analysis, a CT angiogram provides physicians with detailed and accurate images of the vasculature. However, interpreting standard CTA output is a cumbersome time-consuming process.
RAPID CTA automatically provides clear, easy-to-interpret CTA maps that include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple, four-color-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles.
“Our goal is to provide healthcare professionals around the world with the most comprehensive and intuitive suite of imaging solutions possible,” says Don Listwin, CEO of iSchemaView. “With new FDA approval and the release of RAPID CTA, we are making good on that goal. We ensure physicians can take advantage of RAPID’s power whether they choose plain CT, CT angiography, CT perfusion or MR diffusion and perfusion. It’s all about offering them the right imaging solution choice, for the right patient at the right time.”
RAPID CTA also offers remote viewing for physicians in the hospital, at home or on the road. Image maps are immediately available to doctors for review on any desktop or mobile device.
“Many eligible stroke patients with large vessel occlusions must be quickly transferred to a comprehensive stroke center. The new automated RAPID CTA tool makes it easy for community hospitals to quickly identify potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is appropriate for transfer,” says Greg Albers, professor of neurology at Stanford University, director of the Stanford Stroke Center and cofounder of iSchemaView. “With the addition of CTA to RAPID’s FDA indications, hospitals and clinics of all sizes and locations can now use the platform to immediately review images from wherever they are. That’s powerful.”